Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + pemetrexed + platinum + Endostar as second-line therapy for EGFR-TKI–resistant NSCLC
ChiCTR2500106581Phase 2Recruiting
- Sponsor
- Fujian Provincial Hospital
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in non-small cell lung cancer (NSCLC), sponsored by Fujian Provincial Hospital. Primary endpoint: objective response rate. Started Jul 2025; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500106581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106581.